Search research articles
Contact Us
Filters
Showing results (41-50 of 143) with videos related to
Page
of 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2015
Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies
Jan H Beumer, Fei Ding, Hussein Tawbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2014
Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials
Philip A Philip, Kari Chansky, Michael LeBlanc, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
July 14, 2020
Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MS
Julianne L Holleran, Robert A Parise, Jianxia Guo, et al.
Journal of the National Cancer Institute
|
November 11, 2015
Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2015
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Lesley Seymour, Susan Groshen, Gary L Rosner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 19, 2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)
Suresh S Ramalingam, Chandra P Belani, Philip C Mack, et al.
Cancer Chemotherapy and Pharmacology
|
May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions
Lawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual
Holly A Massett, Grace Mishkin, Larry Rubinstein, et al.
Investigational New Drugs
|
January 19, 2010
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
Joleen Hubbard, Charles Erlichman, David O Toft, et al.
Translational Oncology
|
August 9, 2022
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders Initiative
Oluwadamilola Olaku, Barbara A Conley, S Percy Ivy, et al.
Page
of 15
Search research articles
Search
Showing results (41-50 of 143) with videos related to
Sort By:
Page
of 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2015
Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies
Jan H Beumer, Fei Ding, Hussein Tawbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2014
Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials
Philip A Philip, Kari Chansky, Michael LeBlanc, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
July 14, 2020
Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MS
Julianne L Holleran, Robert A Parise, Jianxia Guo, et al.
Journal of the National Cancer Institute
|
November 11, 2015
Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2015
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Lesley Seymour, Susan Groshen, Gary L Rosner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 19, 2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)
Suresh S Ramalingam, Chandra P Belani, Philip C Mack, et al.
Cancer Chemotherapy and Pharmacology
|
May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions
Lawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2016
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual
Holly A Massett, Grace Mishkin, Larry Rubinstein, et al.
Investigational New Drugs
|
January 19, 2010
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
Joleen Hubbard, Charles Erlichman, David O Toft, et al.
Translational Oncology
|
August 9, 2022
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders Initiative
Oluwadamilola Olaku, Barbara A Conley, S Percy Ivy, et al.
Page
of 15